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Abstract. Background: Metastasis suppressor 1 (MTSS1) is
a multi-functional cytoskeletal protein. Recent research
showed that MTSS1 is a potential tumor suppressor in many
types of cancer cells, including kidney and bladder cancer
cells. However, the clinical implication of MTSS1 in human
bladder uroepithelium cell carcinoma (BUCC) and its
potential in suppressing BUCC tumorigenesis remains
undetermined. In the present study, the expression of MTSS1
in human BUCC tissue samples, and correlations between
MTSS1 and pathological grade and stage of the tumors were
examined in BUCC specimens. The function of MTSS1 in
BUCC progression was explored. Materials and Methods:
The mRNA and protein expression of MTSS1 were examined
in 68 BUCC tissue samples with matching adjacent normal
bladder tissues using quantitative real-time PCR and western
blot. Furthermore, the bladder cancer cell line 5637 was
used to determine the anticancer effect of MTSS1. Results:
Lower MTSS1 mRNA expression was seen in BUCC tissues
compared with normal bladder tissues. A lower MTSS1
mRNA level was seen in tumors with high clinical stage and
with high pathological nuclear grade. Likewise, MTSS1
protein expression in normal bladder tissue was significantly
higher than that in BUCC tissue. The protein level of MTSS1
significantly negatively correlated with clinical stage and
pathological nuclear grade of BUCC. Cumulative survival
curves indicated that MTSS1 expression was negatively
correlated with survival time: patients with a high level of
MTSS1 had significantly longer survival time than those with
a low level of MTSS1 (p<0.001). Overexpression of MTSS1
reduced BUCC cell proliferation, cell cycle progression and
colony formation, but had no influence on BUCC cell
apoptosis. Conclusion: These results suggest that
overexpression of MTSS1 suppresses BUCC development,
providing a novel perspective for BUCC tumorigenesis and
a potential therapeutic target for BUCC. 
Bladder uroepithelium cell carcinoma (BUCC), which
accounts for more than 90% of all bladder cancer, is the most
common malignancy of the urinary tract and the ninth most
common malignancy in the world (1). BUCC is a highly
heterogeneous disease, with different histological subtypes
and varying prognosis. The overall and 5-year cancer
survival rates were significantly different among patients
with different pathologic grading, histologic type and AJCC
stage of BUCC (2). Although wide use of advanced imaging
and surgical techniques have improved the clinical outcome
of patients with BUCC, no specific indicator has been found
that predicts morbidity and postoperative recurrence of
BUCC in patients. 
Metastasis suppressor 1 (MTSS1) was originally identified
as a metastasis-suppressor protein with 759 amino acids. Its
C-terminus is identical to the 356 amino acids encoded by
the MTSS1 gene, which is found on human chromosome
8q24.1 and encodes a 5.3 kb mRNA and a polypeptide
predicted to be an actin-binding protein of 356 amino acids
with homology to the Wiscott-Aldrich Syndrome protein
family (3, 4). MTSS1, also known as missing in metastasis
(MIM), MIM-B or basal cell carcinoma-enriched gene 4
(BEG4), was mainly located in the cytoplasm and may be
involved in cytoskeletal organization (5). MTSS1 was
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originally identified as a protein down-regulated in
metastatic bladder carcinoma cell lines (3), and much
evidence has indicated that MTSS1 expression may be
correlated with different types of cancer (6-10). 
We demonstrated that the MTSS1 was a potential tumor
suppressor in human bladder cancer and kidney cancer cells
in our previous studies (11, 12). Thus, MTSS1 may act as a
multifunctional molecule in tumorigenesis and metastasis.
However, the role of MTSS1 in the regulation of the cellular
behavior of bladder cancer is still very much an open
question. In the present study, we investigated the expression
of MTSS1 in a cohort of human bladder cancer tissues and
its correlation with pathological grade, clinical stage and
long-term survival of patients. Furthermore, we examined the
biological effect of MTSS1 on migration and invasion in
bladder cancer cells in vitro.
Materials and Methods 
BUCC specimens. A total of 68 (41 males and 27 females) pairs of
BUCC and normal bladder tissue samples from newly diagnosed
patients who underwent total cystectomy or transurethral resection
of bladder cancer from May 2014 to December 2015 at Peking
University Cancer Hospital were snap-frozen in liquid nitrogen
immediately after surgery. The average age of patients was 52.7±10.4
(range=26-78) years. In the cohort, 52 (76.5%) and 16 (23.5%) cases
were staged as non-muscle-invasive bladder cancer (NMIBC) and
muscle-invasive bladder cancer (MIBC), respectively. Pathological
grades of the cohort were low grade in 48 cases (70.6%) and high
grade in 20 (29.4%). The present study was performed according to
the Declaration of Helsinki and was approved by the Ethics
Committee of Peking University Cancer Hospital, and written
informed consent was obtained from each patient. 
Cell cultures. Bladder cancer cell line 5637 was obtained from the
American Type Culture Collection (Manassas, VA, USA). Cells
were cultured routinely in RPMI-1640, supplemented with 5% fetal
bovine serum, 100 U/ml penicillin and 50 μg/ml streptomycin (all
Gibco, Carlsbad, CA, USA). All cell lines were grown in a
humidified incubator at 37˚C and 5% CO2.
Expression vectors and lentiviral infection. Lentiviral transfected
with MTSS1 expression plasmid (NM_014751) (GV287-RBM5) and
plasmids containing scrambled control sequence (GV287) were
constructed by Genechem Company (Genechem, Shanghai, China).
Bladder cancer 5637 cells were infected with MTSS1 overexpression
lentiviral vectors and negative control lentiviral vectors according to
the manufacturer’s instruction, with 1 μg DNA for 4×105 5637 cells
in a 24-well plate. Five hours after the transfection, the cell culture
medium was replaced with 10% fetal bovine serum. 
Bromodeoxyuridine labeling. For the bromodeoxyuridine (BrdU)
labeling, cells were plated into 96-well culture plates at a 2×104
cells per well in 100 μl cell culture medium and maintained at 37˚C.
The cell growth rate was determined using a BrdU cell proliferation
ELISA kit (Roche Diagnostics, Indianapolis, IN, USA) according to
the manufacturer’s instructions after 1 and 4 days. Each experiment
was performed in triplicate and repeated three times independently.
Cell-cycle analysis. For cell-cycle analysis, cells were seeded on 6-
well plates at 80% confluence and incubated at 37˚C for 24 h. The
cells were harvested, washed with ice-cold phosphate buffered
saline and resuspended in ice-cold 70% ethanol for 30 min. The
cells were then treated with 10 mg/ml RNase at 37˚C for 30 min.
The cells were stained with 10 mg/ml propidium iodide (Sigma, St.
Louis, MO, USA) for 30 min. The DNA content was measured by
flow cytometry.
Colony formation in soft agarose gel. For the cell colony formation
assay, cells were seeded into 6-well plates at 800 cells per well and
cultured at 37˚C for 14 days. The medium was replaced every 3-4
days. Cells were washed twice with phosphate-buffered saline, fixed
with paraformaldehyde, stained with Giemsa (Sigma) for 20
minutes, and washed with ddH2O three times. The plates were
photographed with a microscope. Each experiment was performed
in triplicate and repeated three times independently.
Cell apoptosis detection. For cell apoptosis detection, cells were
seeded on 6-well plates at 80% confluence and incubated at 37˚C
for 24 h. The cells were harvested, washed with ice-cold phosphate-
buffered saline and resuspended in staining buffer. Flow cytometry
was performed to analyze apoptosis. An annexin V-allophycocyanin
(APC) stain assay (eBioscience, Vienna, Austria) was performed
using the manufacturer’s protocol, and the apoptotic cells were
analyzed by flow cytometry.
RNA extraction and quantitative real-time polymerase chain
reaction. Total RNA was extracted from tissues or cells using
TRIzol® reagent (Invitrogen Life Technologies, Carlsbad, CA,
USA). FastQuant RT Kit (With gDNase kit and SuperReal PreMix
Plus (SYBR Green) (TIANGEN BIOTECH, Beijing, P.R. China)
were used. The PCR primers used were as follows: MTSS1 forward:
5’-ACTGGGAATCTGACCACTAT-3’; MTSS1 reverse: 5’-GACCT
GACTGCTAAGGGAC-3’; glyceraldheyde 3-phosphate dehydro-
genase (GAPDH) forward: 5’-TGACTTCAACAGCGACACCCA-
3’, GAPDH reverse: 5’-CACCCTGTTGCTGTAGCCAAA-3’. PCR
cycling conditions were as follows: an Initial denaturation period at
95˚C for 15 min, followed by a two-step PCR program consisting
of denaturation at 95˚C for 10 s and annealing/extension at 60˚C for
32 s for 40 cycles. All samples were normalized against the internal
control (GAPDH) and analyzed using the 2−ΔΔCt method.
Western blot analysis. Total protein was extracted from the cells or
tissue using lysis buffer containing protease inhibitors. Thirty
micrograms of protein from each sample were loaded on 10%
sodium dodecyl sulfonate polyacrylamide gel electrophoresis. The
gels were electrophoresed, and then transferred onto polyvinylidene
difluoride membrane (GE Healthcare, Buckinghamshire, UK), and
blocked with 10% non-fat milk in Tween/Tris-buffered salt solution
[20 mM Tris–Cl, pH 7.5, 0.15 M NaCl and 0.05% Tween-20] for 1
h. Following incubation with the antibody to MTSS1 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) at 4˚C overnight, the
membrane was washed and incubated with IRDye® 800CW Goat
anti-rabbit IgG secondary antibody at room temperature for 2 h
followed by detection using a LiCor Odyssey gel imaging scanner
(LI-COR Biosciences, Lincoln, NE, USA). To verify equal loading
of protein, the blots were re-probed with a primary monoclonal
antibody against GAPDH (Proteintech Group, Inc., Chicago, IL,
USA).
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Statistical analysis. Quantitative analysis of western blot was
performed using the GelDoc-2000 Imaging System (UVi Company,
Cambridge, UK). For protein expression level, the protein ratio (band
density of study protein/band density of GAPDH) was considered as
100% in normal bladder tissues, and that of the other tissues was
expressed as a percentage of that of the normal bladder tissues.
Comparison between groups was performed using one-way analysis
of variance followed by all pairwise multiple comparison procedures
using Bonferroni test and Student t-test or nonparametric test. In
addition, Spearman correlation was used for comparison and
estimation of correlations between MTSS1 protein expression levels
and clinicopathological parameters. Survival curves were constructed
using the Kaplan–Meier method. All data are presented as the
mean±standard deviation, and a value of p<0.05 was regarded as
significant.
Results
Differential expression level of MTSS1 mRNA in BUCC and
normal bladder tissues. The clinical and pathological
characteristics of patients are shown in Table I. In order to
compare the mRNA levels of MTSS1 in human BUCC and
normal bladder tissues, total RNA was isolated from bladder
tissues of 68 patients with BUCC and normal bladder
tissues The transcript level of MTSS1 was examined using
qRT-PCR. The mRNA level of MTSS1 in BUCC tissues was
significantly lower than that of normal bladder tissues.
Furthermore, the mRNA level of MTSS1 was higher in
NMIBC than MIBC, and lower MTSS1 mRNA levels were
seen in BUCC with high pathological grade (p<0.05)
(Figure 1).
Expression profile of MTSS1 protein in BUCC and normal
bladder tissues. To further determine MTSS1 expression
status in BUCC tissues, the protein level of MTSS1 in
BUCC and normal bladder tissues were determined. As
shown in Figure 2, decreased MTSS1 expression was seen
in BUCC tissues compared with normal bladder tissues, and
negativity correlated with clinical stage of BUCC (MIBC vs.
NMIBC, p<0.05). The protein level of MTSS1 was also
significantly negatively correlated with pathological grade of
BUCC (high grade vs. low grade, p<0.05).
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Table I. Baseline clinicopathological characteristics of patients.
Characteristic                                                       Value
Gender                                                                       
   Male                                                              41 (60.3%)
   Female                                                          27 (39.7%)
Age, years                                                  52.7±10.4 (26-78)
Clinical stage                                                            
   NMIBC                                                         52 (76.5%)
   MIBC                                                            16 (23.5%)
Pathological grade                                                    
   Low                                                               48 (70.6%)
   High                                                              20 (29.4%)
Follow-up, years                                             2.84 (0.9-3)
MIBC: Muscle-invasive bladder cancer; NMIBC: non-muscle-invasive
bladder cancer. Data are the mean±SD, median (range) or  number (%).
Figure 1. Lower expression of metastasis suppressor 1 (MTSS1) mRNA in patients with bladder uroepithelium cell carcinoma (BUCC). The relative
expression of MTSS1 mRNA in BUCC tissues was significantly lower than that of normal bladder tissues. Furthermore, the mRNA level of MTSS1
was higher in non-muscle-invasive bladder cancer (NMIBC) than muscle-invasive bladder cancer (MIBC), *p<0.05 vs. Normal, #p<0.05 vs. NMIBC
(A). Furthermore, the mRNA level of MTSS1 was higher in low pathological grade cancer than high pathological grade cancer tissues, *p<0.05
vs. Normal, #p<0.05 vs. low grade. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) acted as an internal loading control. Each sample was
detected by triplicates.
Decrease of MTSS1 expression was a predictor of poor
survival of patients with BUCC. Kaplan–Meier survival
analysis was used to determine the overall survival of
patients according to MTSS1 expression. Regardless of
cancer classification of MIBC and NMIBC, patients with
low MTSS1 expression had significantly shorter survival
than those with high MTSS1 expression (Figure 3A).
Furthermore, regardless of cancer grade, patients with low
MTSS1 expression also had significantly shorter survival
than those with high MTSS1 expression (Figure 3B). These
findings suggest that a decrease of MTSS1 expression in
bladder cancer predicts poor survival.
Overexpression of MTSS1 reduced bladder cancer cell
proliferation, cell cycle progression and colony formation in
vitro. To explore the role of MTSS1 in bladder cancer cell
proliferation, the 5637 cells were infected with MTSS1
overexpression lentiviral vectors and control lentiviral vectors.
As shown in Figure 4, both the mRNA and protein expression
levels were significantly up-regulated in 5637 cells after
infection with the lentiviral vectors for MTSS1 overexpression.
The BrdU proliferation assay was conducted to confirm the
effect of MTSS1 overexpression on bladder cancer cells
proliferation. As shown in Figure 5A, overexpression of
MTSS1 reduced cancer cell proliferation significantly. Cell
cycle analysis and colony formation analysis were used to
examine if MTSS1 overexpression influences bladder cancer
cell growth. Figure 5B demonstrates that there was a
significant increase in the rate of G2/M phase cells when
MTSS1 was overexpressed, but there was no significant
influence on cells in S and G1 phase. Moreover, 5637 cells
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Figure 3. Low metastasis suppressor 1 (MTSS1) expression predicted
poor survival of patients with bladder uroepithelium cell carcinoma
(BUCC). Patients with muscle-invasive bladder cancer (MIBC) with low
MTSS1 expression had significantly shorter survival than those with
NMIBC with high MTSS1 expression. B: Patients with high pathological
grade cancer with low MTSS1 expression also had significantly poor
survival than those with low pathological grade cancer with high
MTSS1 expression.
Figure 2. The expression of metastasis suppressor 1 (MTSS1) protein
decreased in cancer tissues of high pathological grade. A: Typical
results of western blot showed that MTSS1 protein level decreased in
non-muscle-invasive bladder cancer (NMIBC) tissues, and the protein
level was significantly lower in muscle-invasive bladder cancer (MIBC)
tissues than that in NMIBC tissues. B: The MTSS1 protein level was
also lower in cancer tissues with low pathological grade, and the
protein level was significantly lower in cancer tissues with high
pathological grade.
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Figure 5. Up-regulation of metastasis suppressor 1 (MTSS1) reduces cell proliferation. A: Quantitative analysis of bromodeoxyuridine (BrdU)-
positive cell number was reduced in 5637 cells transfected with MTSS1 overexpression lentiviral vectors (OE) compared with the negative control
lentiviral vector (NC) group. B: The quantitative analysis demonstrated that overexpression of MTSS1 significantly reduced the number of cells in
the G2/M phase. C: OE cells formed fewer and smaller colonies per plate than the NC cells after 14 days seeded. n=3 per group, *p<0.05 vs. NC
group. Con: 5637 cells without any treatment.
Figure 4. Overexpression of metastasis suppressor 1 (MTSS1) in 5637 cells. The relative expression of MTSS1 mRNA significantly increased in 5637
cells after infection with MTSS1 overexpression lentiviral vectors. Con: 5637 cells without any treatment, NC: 5637 cells infected with negative
control lentiviral vectors, and OE: 5637 cells infected with MTSS1 overexpression lentiviral vectors. B. Western blot analysis shows that MTSS1
protein level was significantly increased in the OE cells compared to NC cells. n=3 per group, *p<0.05 vs. NC group.
showed signiﬁcantly less colony formation when MTSS1 was
overexpressed (Figure 5C and D). 
Up-regulation of MTSS1 had no influence on apoptosis of
bladder cancer cells. To further elucidate the role of MTSS1
in bladder cancer cell apoptosis, 5637 cells infected with
MTSS1 overexpression lentiviral vectors were subjected to
annexin V-APC staining and flow cytometric analysis. Figure
6 demonstrates that MTSS1 overexpression in 5637 cells had
no significant effects on the cellular apoptosis rate.
Discussion
BUCC is one of the most common types of cancer, and an
estimated 74,000 new cases are diagnosed per year. Since
the molecular heterogeneity of BUCC is considered as one
of the most important factors responsible for large variation
in the response to clinical treatment, molecular diagnosis
becomes more and more important in patients suffering
BUCC (13). In our previous study, we confirmed reduced
expression of MTSS1 in human bladder cancer tissues using
immunohistochemical analysis and also found a decrease in
the mRNA expression in bladder cancer cell lines (12). In
this study, we further confirmed decreased expression of
MTSS1 in bladder cancer tissues and cell lines, especially in
MIBC and high-grade BUCC. We demonstrated that low
MTSS1 expression was a predictor of poor patient survival,
and overexpression of MTSS1 reduced BUCC cell
proliferation, cell cycle progression and colony formation,
but had no influence on BUCC cell apoptosis.
The role of MTSS1 in cancer diagnosis and progression
has been elucidated. There are multiple published studies
indicating cancer-suppressive functions of MTSS1 in a
variety of cancer models. Kayser et al. found that the
expression of MTSS1 significantly increased in non-small-
cell lung carcinomas compared with normal lung, and
MTSS1 expression was inversely correlated with cancer
stage and histological grading. In addition, patients with low
MTSS1 expression had a significantly worse outcome (14).
Zeleniak et al. demonstrated that primary pancreatic ductal
adenocarcinoma displayed higher MTSS1 expression levels
than did metastatic pancreatic ductal adenocarcinoma (15).
Another report also showed that loss of MTSS1 expression
was associated with lymph node metastasis and poor
differentiation of hilar cholangiocarcinoma (16), and high
expression of MTSS1 suppressed the invasive, migratory,
growth and adhesive properties of breast cancer cell lines
(17). Similarly, data from our previous study demonstrated
MTSS1 expression to be reduced in human kidney cancer
cells, and to be are inversely correlated with the growth,
invasion, adhesion and migration of kidney cancer cells (11).
However, there are conflicting data on whether MTSS1
expression is an indicator of good or poor prognosis in
patients with advanced cancer. In hepatitis B-related
hepatocellular carcinoma, elevated MTSS1 expression was
found to be associated with cancer metastasis and poor
prognosis (18). Up-regulation of MTSS1 expression in
colorectal cancer tissues was also significantly correlated
with poor differentiation, tissue invasion, high preoperative
carcinoembryonic antigen level, presence of lymph node
metastasis and high TNM stage (19).
Interestingly, our present data showed an increase in the
proliferative potential of BUCC cells with decreased MTSS1
expression, but intrinsically overexpression of MTSS1 did not
result in any difference in apoptosis. This suggested that
MTSS1 mainly functions as a specific proliferation suppressor
protein in BUCC, regulating cell proliferation and cancer
growth. The mechanisms for down-regulation of MTSS1 in
BUCC are not fully understood. Actin polymerization plays a
very important role in cell polarization, cytokinesis and cell
adhesions, which is ultimately implicated in a variety of stages
of cancer progression. Multiple studies revealed that MTSS1
may act as a cytoskeletal scaffold protein to regulate
cytoskeletal dynamics through interaction with other proteins.
It can regulate cell motility by modulating different actin-
related protein (ARP)2/3 activators (20). Overexpression of
MTSS1 increased the formation of lamellipodia, membrane
ruffles, and filopodia-like structures (21). In addition, MTSS1
was reported to behave as a sonic hedgehog-responsive gene,
which association with the Gli complex during both
development and tumorigenesis (22). Methylation is also
known to be involved in the down-regulation of MTSS1.
Yamashita et al. found when gastric cancer cells were treated
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Figure 6. Overexpression of metastasis suppressor 1 (MTSS1) had no
effect on cell apoptosis. Quantification of apoptotic cell number
indicated that cells transfected with MTSS1 overexpression lentiviral
vectors (OE) had no effect on 5637 cell apoptosis when compared with
the negative control lentiviral vector (NC) group, n=3 per group. Con:
5637 cells without any treatment.
with the demethylating agent 5-aza-2’-deoxycytidine, MTSS1
expression level increased significantly (23).
In summary, our current study demonstrated that MTSS1
plays an important role in BUCC tumorigenesis and
development. These findings enrich our understanding of the
molecular function of MTSS1 underlying BUCC
progression, and is useful for understanding the role of
MTSS1 in the proliferation of BUCC cells. MTSS1 therefore
could be a promising diagnostic biomarker and therapeutic
target for BUCC. Further studies are necessary to determine
MTSS1-related signaling pathways in BUCC progression.
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